592 Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
December 5, 2024 at 8:55 PM
592 Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
766 Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
December 5, 2024 at 8:55 PM
766 Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
672 Immune-MRD Status Informs Tumor-MRD Outcome Prognostication in Multiple Myeloma Patients on Lenalidomide Maintenance
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
December 5, 2024 at 8:55 PM
672 Immune-MRD Status Informs Tumor-MRD Outcome Prognostication in Multiple Myeloma Patients on Lenalidomide Maintenance
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
591 NF-Kb Pathway Activation Driven By TRAF3 Loss Mediates Resistance to Anti-BCMA T-Cell Based Therapies in Multiple Myeloma
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
December 5, 2024 at 8:55 PM
591 NF-Kb Pathway Activation Driven By TRAF3 Loss Mediates Resistance to Anti-BCMA T-Cell Based Therapies in Multiple Myeloma
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
251 DNA Methylation Analysis of Commpass Reveals Distinct Epigenetic Programs of High-Risk Disease
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
December 5, 2024 at 8:55 PM
251 DNA Methylation Analysis of Commpass Reveals Distinct Epigenetic Programs of High-Risk Disease
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
248 Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
December 5, 2024 at 8:55 PM
248 Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
247 Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
December 5, 2024 at 8:55 PM
247 Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
358 Combination with Cytotoxic Therapy and Checkpoint Blockade Overcomes Primary Resistance to BCMA Bispecific Antibody Therapy and Leads to Durable Remission of Vk*MYC Multiple Myeloma
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
December 5, 2024 at 8:55 PM
358 Combination with Cytotoxic Therapy and Checkpoint Blockade Overcomes Primary Resistance to BCMA Bispecific Antibody Therapy and Leads to Durable Remission of Vk*MYC Multiple Myeloma
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
1025 Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
December 5, 2024 at 8:53 PM
1025 Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
1021 Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
December 5, 2024 at 8:53 PM
1021 Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
1031 Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
December 5, 2024 at 8:53 PM
1031 Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
362 Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) V in Patients with Transplant-Ineligible NDMM or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
December 5, 2024 at 8:51 PM
362 Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) V in Patients with Transplant-Ineligible NDMM or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
770 Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
December 5, 2024 at 8:51 PM
770 Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
769 Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
December 5, 2024 at 8:51 PM
769 Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
673 IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
December 5, 2024 at 8:51 PM
673 IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
493 Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
December 5, 2024 at 8:51 PM
493 Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
497 Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
December 5, 2024 at 8:51 PM
497 Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
494 Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in NDMM As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
December 5, 2024 at 8:51 PM
494 Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in NDMM As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...